Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 159,301 | 145,276 | 144,923 | 149,745 | 136,709 |
| Cost of Goods | 62,507 | 54,470 | 53,467 | 55,115 | 56,398 |
| Gross Profit | 96,794 | 90,806 | 91,456 | 94,630 | 80,311 |
| Operating Expenses | 62,462 | 43,805 | 42,449 | 33,057 | 35,696 |
| Operating Income | 34,839 | 47,471 | 49,474 | 61,688 | 45,013 |
| Interest Expense | 18,394 | 15,587 | 17,339 | 19,281 | 20,768 |
| Other Income | -865 | -2,787 | 4,487 | 4,303 | 4,538 |
| Pre-tax Income | 15,580 | 29,097 | 36,622 | 46,710 | 28,783 |
| Income Tax | 6,245 | 9,491 | 8,909 | 14,770 | 8,149 |
| Net Income Continuous | 9,335 | 19,606 | 27,713 | 31,940 | 20,634 |
| Net Income | $9,335 | $19,606 | $27,713 | $31,940 | $20,634 |
| EPS Basic Total Ops | 0.29 | 0.60 | 0.86 | 0.95 | 0.61 |
| EPS Basic Continuous Ops | 0.29 | 0.60 | 0.86 | 0.95 | 0.61 |
| EPS Diluted Total Ops | 0.27 | 0.52 | 0.71 | 0.93 | 0.53 |
| EPS Diluted Continuous Ops | 0.23 | 0.49 | 0.67 | 0.87 | 0.49 |
| EPS Diluted Before Non-Recurring Items | 1.48 | 1.43 | 1.32 | N/A | N/A |
| EBITDA(a) | $76,072 | $82,215 | $84,493 | $96,583 | $81,596 |